15 June 2017 – Parsortix breakthrough
The company has announced that researchers using the group’s Parsortix system have found a rare cell in the blood of prostrate cancer patients and discovered that the number of these cells in the blood has been shown to correlate closely with increased patient survival. This is the first time that the presence of these cells in the blood has been shown to be connected to cancer prognosis. This is a significant breakthrough for the technology and we continue to rate the shares as a LONG TERM BUY.